Introduction
============

Barratta \[[@r1]\] first described aniridia in 1818 (OMIM [106210](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=106210)). Although called aniridia (Greek for absence of the iris), this disorder is not just an isolated defect in iris development but is a panocular disorder that involves the lens, optic nerve, cornea, anterior chamber, and retina \[[@r2]\]. Aniridia occurs in the general population at a frequency of approximately 1 in 64,000--96,000, and two-thirds of cases are familial with autosomal dominant inheritance with complete penetrance but variable expressivity \[[@r3]\].

Paired box gene 6 (*PAX6*), a member of the paired box gene family, is located on chromosome 11p13. *PAX6* is divided into 14 exons that span over 22 kb in length \[[@r4]\]. The polypeptide product possesses several functional domains: a paired domain and a homeodomain separated by a linker segment and followed by a COOH-terminal region rich in proline, serine, and threonine \[[@r5]\]. The paired domain, which is encoded by exons 5--7 of *PAX6*, comprises two structurally distinct subdomains, the relatively conserved NH~2~ terminal (NTS) and the variable COOH terminal \[[@r6],[@r7]\]. *PAX6* plays a major role in the organization of the developing eye \[[@r3]\], and various heterozygous mutations in *PAX6* have been identified in patients with aniridia. To date over 20 different *PAX6* mutations, which have been reported in the Human *PAX6* Allelic Variant Database \[[@r8]\], are associated with aniridia and congenital cataract.

In this study, we analyzed the coding sequences of *PAX6* in a large Chinese family and identified a novel frameshift mutation that causes aniridia and cataract.

Methods
=======

Patients
--------

We investigated a large family that originated from the central region of China. Seven living patients with aniridia and congenital cataract were identified. Informed consent was obtained from the participants in accordance with the study protocols approved by the ethics committee of Union Hospital of Huazhong University of Science and Technology, Wuhan, China. The proband in this family received a complete ophthalmic evaluation, and the other five subjects (ocular data of II-11 could not be obtained) underwent ocular slit-lamp examination at Union Hospital.

Mutation screening
------------------

Venous blood (5 ml) was collected from the participants, and total human genomic DNA was isolated with the DNA Isolation Kit for Mammalian Blood (Roche Diagnostic Company, Indianapolis, IN). Considering that the *PAX6* mutation is a genetic factor common to hereditary aniridia and at least 20 different mutations of *PAX6* are responsible for both aniridia and congenital cataract, we carried out mutation screening in the *PAX6* gene directly without performing linkage analysis. Because the ten coding exons (exon 5--14) have been thought to be the hot spots for *PAX6* mutation \[[@r8]\], eight pairs of primers ([Table 1](#t1){ref-type="table"}) were used to amplify these regions. Briefly, amplification was performed in the PTC-200 thermal cycler (MJ Research Inc., Waterdown, MA) in a 25-μl reaction mixture containing 1.5 mM MgCl~2~, 0.2 mM of each dNTP (Qiagen, Hilden, Germany), 0.5 μM primers, 1 U of Taq DNA polymerase (Qiagen), and 50 ng of genomic DNA. PCR was performed as follows: an initial denaturation step was carried out for 3 min at 94 °C, nine cycles of 30 s at 94 °C, 30 s at the respective annealing temperature (see [Table 1](#t1){ref-type="table"}) and 30 s at 72 °C, followed by the same 27 cycles with a separate annealing temperature ([Table 1](#t1){ref-type="table"}). Direct bidirectional resequencing of all PCR-amplified products was performed with the BigDye Terminator Cycle Sequencing v3.1 kit (Applied Biosystems, Foster City, CA) and electrophoresed on an ABI PRISM 3730 Genetic Analyzer (Applied Biosystems). Sequencing results from the subjects and *PAX6* consensus sequences from the [NCBI](http://www.ncbi.nlm.nih.gov/genbank/index.html) human genome database ([NM_000280.3](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=NM_000280.3)) were compared by using [BLAST](http://www.ncbi.nlm.nih.gov/blast/) analysis. Mutation description followed the nomenclature recommended by the [Human Genomic Variation Society](http://www.hgvs.org/mutnomen/).

###### Primers used for polymerase chain reaction amplification and sequencing of *PAX6*.

  ** **    ** **                        ** **                        **Annealing temperature °C**   ** **   
  -------- ---------------------------- ---------------------------- ------------------------------ ------- -----
  5        GGCTGGTGGTCCTGTTGTCCTT       CGAGCCCGAAGTCCCAGAAAG        61.5                           55      483
  6, 7     AAGCAAGGTCAGCACAAAAATAAATT   GGAGGAGGTAAAGAGGAGAGAGCATT   60.5                           54      648
  8        TAAGGTTGTGGGTGAGCTGAGATG     GGGAGAGTAGGGGACAGGCAAAGG     61.5                           55      315
  9        TTTGGTGAGGCTGTCGGGATATAAT    TGCCCAGAGAAATAAAAAGACAGAAA   61.5                           55      415
  10       TTGGTTGGAGGTAATGGGAGTGG      TGGCAGCAGAGCATTTAGCAGAC      61.5                           55      334
  11, 12   GGGGCTGGGCTCGACGTAG          GCCACCACCAGCCGCACTTA         65                             60      438
  13       GGGGCTGTGGCTGTGTGATGT        CCCCAGGGACAAGGAAAGCAA        61.5                           55      333
  14       CCAAACATGCAAACAAACAGAGGA     TTCCAACTGATATCGTGCCTTCTG     61.5                           55      570

Single-strand conformation polymorphism analysis
------------------------------------------------

The novel variation detected in exon 5 of *PAX6* was further evaluated in 28 available family members as well as normal control subjects by using single-strand conformation polymorphism (SSCP) analysis, as described previously \[[@r9]\]. Briefly, 2 μl of undigested PCR products was mixed with 4 μl of the degenerating loading buffer, denatured at 95 °C for 10 min and immediately placed on ice; then loaded on 5% polyacrylamide gels, and the DNA samples were separated by electrophoresis overnight at 150 V. The DNA bands were visualized by silver staining.

Sequencing of variants
----------------------

We sequenced all variants detected by SSCP. Following electrophoresis, the DNA bands of interest were excised, taking care to remove as much excess gel as possible. The gel slices containing the PCR products with 100 μl of dH~2~O were crushed and melted at 65 °C for 4--5 h. PCR was performed as described above. PCR products were sequenced using the BigDye Terminator v3.1 kit and the ABI 3730 sequencer.

Results
=======

Clinical findings
-----------------

We identified a large Chinese family with 49 living members in four generations ([Figure 1](#f1){ref-type="fig"}). Bilateral total aniridia, congenital cataract, congenital nystagmus and optic nerve hypoplasia were present in the proband ([Figure 2](#f2){ref-type="fig"}). Ophthalmic manifestations of affected members are listed in [Table 2](#t2){ref-type="table"}, and all six patients had bilateral total aniridia and congenital posterior subcapsular cataract. Corneal pannus was present in three patients ([Figure 2](#f2){ref-type="fig"}), and congenital nystagmus was present in two patients.

![Pedigree of a Chinese family with autosomal-dominant aniridia. Affected males and females are indicated by filled squares and circles, respectively. Normal individuals are shown as empty symbols. Deceased individuals are indicated by slashes (/). The proband is indicated by an arrow.](mv-v16-1141-f1){#f1}

![Slit-lamp aspects of the ocular anterior segment of patients. The proband (III-25) exhibits aniridia without iris remnants (**A**); the affected family member (II-13) presents corneal pannus (**B**); the normal subject (III-26) shows a complete iris (**C**).](mv-v16-1141-f2){#f2}

###### Ocular phenotypes in six aniridia patients from a Chinese family.

  **Patient**   **Age (years)/sex**   **Aniridia**   **Cataracts**   **Corneal pannus**   **Nystagmus**
  ------------- --------------------- -------------- --------------- -------------------- ---------------
  II-13         54/F                  \+             \+              \+                   \-
  III-5         41/F                  \+             \+              \+                   \+
  III-7         40/M                  \+             +\*             \+                   \-
  III-25\*\*    31/F                  \+             \+              \-                   \+
  IV-3          12/F                  \+             \+              \-                   \-
  IV-4          12/F                  \+             \+              \-                   \-

The asterisk indicates after left cataract extraction and the double asterisk indicates the proband.

Mutation analysis
-----------------

Direct bidirectional sequencing of *PAX6* in all affected patients revealed a heterozygous 17 bp deletion (c.475_491delGGCCGTGCGACATTTCC) within the paired domain in exon 5. The c.475_491del17 generates a frameshift and a premature termination 12 codons downstream (p.Arg38ProfsX12). SSCP analysis also demonstrated that affected members in the family carried this mutation, but the unaffected members of the family and 100 normal Chinese Han controls did not carry the mutation ([Figure 3](#f3){ref-type="fig"}). In all affected family members, the same heterozygous was confirmed by sequencing the extra bands of PCR-SSCP products ([Figure 4](#f4){ref-type="fig"}). These results suggest that this novel mutation of *PAX6* is not a rare polymorphism but a causative mutation for autosomal-dominant congenital aniridia and congenital cataract in this Chinese family.

![SSCP analysis of *PAX6* mutation in exon 5. Each affected individual has one more band than normal family members. The arrow indicates the extra band of the index patient (III-25).](mv-v16-1141-f3){#f3}

![Sequence of the PCR product of exon 5 in *PAX6*. The top chromatogram represents the sequence of a normal family member (normal). The middle chromatogram shows a reading frame shift in the proband (III-25, heterozygous), and the arrow indicates the initiation of the mutation site (beginning of overlapping peaks). The bottom chromatogram exhibits the sequence of the extra band of the SSCP removed from the gel (mutant), and the arrow indicates the location of the mutation.](mv-v16-1141-f4){#f4}

Discussion
==========

In the present study, the identified novel mutation (c.475_491del17) generates a frameshift and a premature termination 12 codons downstream (p.Arg38ProfsX12). The novel mutation in *PAX6* predicted to result in a transcript that is recognized by the nonsense-mediated mRNA decay system \[[@r10]\], leading to a half reduction of the full-length PAX6 protein. This result conforms to genotype--phenotype correlation analysis, suggesting that mutations that introduce a premature termination codon (PTC) into the open reading frame usually result in the aniridia phenotype \[[@r11]\].

The NTS of the paired domain is highly conserved and plays an important role in contacting with the DNA. There is a helix-turn-helix (HTH) unit, containing a β turn and three α helices (helix 1, 2 and 3, residues 23-35, 40-45, and 50-63, respectively) in the NTS; this helix-turn-helix unit makes critical contacts in sugar phosphate backbone, major groove and minor groove. Among those residues, Arg38, Pro39 and Cys40 (Arg38 and Pro39 are in the turn between helices 1 and 2; Cys40 is a part of helix 2), contact with the sugar phosphate backbone of the target DNA \[[@r12]\]. Interestingly, in our patients the deletion mutation (c.475_491del17, p.Arg38ProfsX12) affects residues (Arg38 to Ser43) involving the above-mentioned three amino acids (Arg38, Pro39, and Cys40). Clinical data show that although there are different symptoms in different patients, they have common and severe congenital anomalies in eye development, including the near absence of iris and posterior subcapsular cataract. We evaluated seven unique mutations from the Human *PAX6* Allelic Variant Database \[[@r8]\] that refer to these three amino acids ([Table 3](#t3){ref-type="table"}) \[[@r13]-[@r19]\]. Atchaneeyasakul et al. \[[@r16]\] reported that a novel insertion/deletion mutation (c.474_480del12insGA) detected in a Thai familial aniridia patient affects the three residues completely. The patient had normal best corrected visual acuity but other ocular abnormalities, including partial aniridia, juvenile glaucoma, posterior polar cataracts, corneal pannus, foveal hypoplasia, and ptosis. With the exception of one case \[[@r14]\], it appears that mutations impacting one or two of the three amino acids are associated with an isolated defect in iris development \[[@r13],[@r17]-[@r19]\]. In that anomalistic case \[[@r14]\], the patient with complex eye phenotypes was found to have mutations not only in *PAX6* but also in neurofibromin 1 (*NF1*) and orthodenticle homeobox 2 (*OTX2*). In addition, a neighboring mutation (p.41_43delAspIleSer) generates the aniridia phenotype only \[[@r20]\]. We presume the region that the residues (Arg38, Pro39, and Cys40) are in contact with play an important role in the process of optical development, and an anomaly of this region may generate a complex phenotype of ocular organs. Furthermore, mutations that affect residues Asp41-Ser43 ([Table 3](#t3){ref-type="table"}) \[[@r20]-[@r24]\] lead to a consistent aniridia phenotype; two of these mutations result in aniridia accompanied with cataract \[[@r23],[@r24]\]. Although approximate 11% of the mutations in the database do not result in aniridia or cataract, several mutations that refer to the 17 nucleotides deleted in our patients generate both the aniridia and congenital cataract phenotype.

###### Mutations impacting on residues (Arg38 to Ser43) cause different phenotypes.

  **Genotype**          ** **                 ** **                                                             
  --------------------- --------------------- ----------------------------------------------------------------- ------------
  c.471del9             p.37_39del            Aniridia                                                          \[[@r12]\]
  c.474C\>T             p.Arg38Trp            Aniridia, microphthalmia, nystagmus, cataract                     \[[@r13]\]
  c.474delC             p.Arg38GlyfsX16       Aniridia                                                          \[[@r14]\]
  c.474_485del12insGA   p.Arg38GlufsX13       Aniridia, glaucoma, cataract, foveal hypoplasia, corneal pannus   \[[@r15]\]
  c.476_483del8         p.Pro39HisfsX14       Aniridia                                                          \[[@r16]\]
  c.478insCC            p.Cys40ArgfsX15       Iris hypoplasia                                                   \[[@r17]\]
  c.482C\>A             p.Cys40X              Aniridia                                                          \[[@r18]\]
  c.483_491del9         p.41_43delAspIleSer   Aniridia                                                          \[[@r19]\]
  c.484A\>G             p.Asp41Gly            Iris hypoplasia, nystagmus                                        \[[@r20]\]
  c.486delA             p.Ile42PhefsX12       Aniridia, glaucoma                                                \[[@r21]\]
  c.487T\>G             p.Ile42Ser            Aniridia, nystagmus, congenital cataract                          \[[@r22]\]
  c.489T\>C             p.Ser43Pro            Aniridia, cataract, nystagmus                                     \[[@r23]\]

This study identified a novel deletion mutation of *PAX6* in a Chinese family with aniridia and congenital cataract. This finding expands the mutation spectrum of *PAX6* and is useful and valuable for genetic counseling and prenatal diagnosis in families with aniridia accompanied with congenital cataract.
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